NMDA Receptor regulation of memory and behavior in humans

Hippocampus

Volumn 11, Issue 5, 2001, Pages 529-542

  Newcomer, John W ^a   Krystal, John H ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cognition; Glutamate; Memory; NMDA; Psychosis; Schizophrenia

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; CYCLOSERINE; KETAMINE; LAMOTRIGINE; LORAZEPAM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OLANZAPINE;

AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; BEHAVIOR DISORDER; BRAIN FUNCTION; CLINICAL FEATURE; CLINICAL OBSERVATION; COGNITION; CONTROLLED STUDY; DISSOCIATION; HUMAN; IN VIVO STUDY; LEARNING; LONG TERM MEMORY; MEMORY; MEMORY CONSOLIDATION; METHODOLOGY; MOUSE; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; RAT; SCHIZOPHRENIA;

BEHAVIOR; COGNITION; HUMANS; MEMORY; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 0035179658     PISSN: 10509631     EISSN: None     Source Type: Journal    
DOI: 10.1002/hipo.1069     Document Type: Article

References (188)

1. Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort
2. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine
3. Schizophrenia, sensory gating, and nicotinic receptors
4. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics
5. Phencyclidine, dizocilpine, and cerebrocortical neurons
6. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: Support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists
7. The phenomenology of experimentally induced amphetamine psychosis-preliminary observations
8. Amphetamine psychosis: Behavioral and biochemical aspects
9. Dissociation of storage and rehearsal in verbal working memory: Evidence from PET
10. Observations on the psychotomimetic effects of sernyl
11. Phencyclidine
12. The behavioral pharmacology of phencyclidine
13. A synaptic model of memory: Long-term potentiation in the hippocampus
14. Early neuroleptic response: Clinical profiles and plasma catecholamine metabolites
15. A parametric study of prefrontal cortex involvement in human working memory
16. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method
17. Acute behavioral effects of MK-801 in rhesus monkeys: Assessment using an operant test battery
18. A novel NMDA antagonist, MK-801, impairs performance in a hippocampal-dependent spatial learning task
19. Effect of chlorpromazine or haloperidol on formation of 3-methoxytryramine and normetanephrine in mouse brain
20. Activity-dependent decrease in NMDA receptor responses during development of the visual cortex
21. Glutamate neurotoxicity and diseases of the nervous system
22. Excitotoxic cell death
23. Comparison of phencyclidine hydrochloride (sernyl) with other drugs
24. Activation of prefrontal cortex in a nonspatial working memory task with functional MRI
25. Temporal dynamics of brain activation during a working memory task
26. Memories of NMDA receptors and LTP
27. Multifocal brain damage induced by phencyclidine is augmented by pilocarpine
28. Dissociative anesthesia: Further pharmacologic studies and the first clinical experience with the phencyclidine derivative CI-581
29. An open trial of glycine as an adjunct to neuroleptics in the chronic treatment of refractory schizophrenia
30. The glutamatergic dysfunction hypothesis for schizophrenia
31. Intraventricular administration of the NMDA antagonist APV disrupts learning of an odour aversion that is potentiated by taste
32. Learning impairment in rats by N-methyl-D-aspartate receptor antagonists
33. The effect of 1-arylcyclohexylamine (sernyl) on twelve normal volunteers
34. The NMDA receptor antagonist D-2-amino-5-phosphonopentanoate (D-AP5) impairs spatial learnings and LTP in vivo at intracerebral concentrations comparable to those that block LTP in vitro
35. A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine
36. Abnormal mental states induced by phenocyclidine as a model of schizophrenia
37. Glycine site agonist of the NMDA receptor: A review
38. The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: A prospective study
39. Competitive and non-competitive NMDA antagonists induce similar limbic degeneration
40. The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias
41. The PCP psychosis: Prolonged intoxication or drug-precipitated functional illness?
42. Antipsychotic drugs block phencyclidine receptor-mediated neurotoxicity
43. 2 adrenergic agonists prevent MK-801 neurotoxicity
44. Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity
45. 2A receptors prevent NMDA antagonist neurotoxicity
46. The glutamate synapse in neuropsychiatric disorders: Focus on schizophrenia and Alzheimer's disease
47. Glycine agonists: What can they teach us about schizophrenia?
48. Glutamatergic transmission: Therapeutic prospects for schizophrenia and Alzheimer's disease
49. Increased neocortical neurofibrillary tangle density in Alzheimer's disease subjects with psychosis
50. Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity
51. Acute behavioral effects of phencyclidine on rhesus monkey performance in an operant test battery
52. On the use and abuse of LSD
53. LSD: The bridge from human to animal
54. Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: Effects of schizophrenia
55. Circuit-specific alterations of N-methyl-D-aspartate receptor subunit 1 in the dentate gyrus of aged monkeys
56. Ketamine: Behavioral effects of subanesthetic doses
57. The psychedelic model of schizophrenia: The case of N,N-dimethyltryptamine
58. NMDA receptor antagonists decrease GABA outflow from the septum and increase acetylcholine outflow from the hippocampus: A microdialysis study
59. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia
60. D-cycloserine added to clozapine for patients with schizophrenia
61. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia
62. N-methyl-D-aspartate mediated responses decrease with age in Fischer 344 rat brain
63. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia
64. Short-term and Long-term Effects of N-methyl-D-aspartate receptor hypofunction
65. Safety and tolerability of the glutamate antagonist CGS 19755 (selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial
66. NMDA-dependent modulation of CA1 local circuit inhibition
67. Effects of oral clonidine premedication on side effects of intravenous ketamine anesthesia: A randomized, double-blind, placebo-controlled study
68. Selective memory impairment by phencyclidine in rats
69. Competitive as well as uncompetitive N-methyl-D-aspartate receptor antagonists affect cortical neuronal morphology and cerebral glucose metabolism
70. Attention, learning, and personality during ketamine emergence: A pilot study
71. MK-801 increases endogenous acetylcholine release in the rat parietal cortex: A study using brain microdialysis
72. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia
73. D-CPPene (SDZ EAA 494), a competitive NMDA antagonist. Results from animal models and first results in humans
74. Activation and desensitization of glutamate-activated channels mediating fast excitatory synaptic currents in the visual cortex
75. Cloned glutamate receptors
76. MK-801-induced neuronal damage in rats
77. Formation of temporal memory requires NMDA receptors within CA1 pyramidal neurons
78. NMDA receptor mRNA correlation with antemortem cognitive impairment in schizophrenia
79. Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia
80. Motor neuron degeneration induced by excitotoxin agonists has features in common with that seen in the SOD-1 transgenic mouse model of amyotrophic lateral sclerosis
81. Amphetamine psychosis and psychotic symptoms
82. Ketamine-can chronic use impair memory?
83. Recent advances in the phencyclidine model of schizophrenia
84. Recent advances in the phencyclidine model of schizophrenia
85. Amelioration of negative symptoms in schizophrenia by glycine
86. Isoflurane and propofol block neurotoxicity caused by MK-801 in the rat posterior cingulate/retrosplenial cortex
87. Lamotrigine prevents NMDA antagonist neurotoxicity
88. Sernyl (CI-395) in clinical anaesthesia
89. Differential effects of sigma and phencyclidine receptor ligands on learning
90. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis
91. Phencyclidine poisoning in young children
92. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: Implications for schizophrenia
93. Selective impairment of long-term but not short-term conditional fear by the N-methyl-D-aspartate antagonist APV
94. Effects of amygdala, hippocampus, and periaqueductal gray lesions on short- and long-term contextual fear
95. Reduction of cerebrospinal fluid glutamic acid in Huntington's chorea and in schizophrenic patients
96. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia
97. Excessive cerebrocortical release of acetylcholine induced by NMDA antagonists is reduced by GABAergic and alpha2-adrenergic agonists
98. The NMDA-receptor antagonist CPP abolishes neurogenic "wind-up pain" after intrathecal administration in humans
99. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses
100. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans
101. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans
102. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects
103. Increased dopamine transmission in schizophrenia: Relationship to illness phases
104. Dexmedetomidine premedication attenuates ketamine-induced cardiostimulatory effects and postanesthetic delirium
105. Provocative tests with psycho-stimulant drugs in schizophrenia
106. Effects of phencyclidine on excitatory amino acid activation of spinal interneurones in the cat
107. Excitatory amino acids and phencyclidine-like drugs
108. Study of a new schizophrenomimetic drug-sernyl
109. Model psychoses and schizophrenia
110. The aging of the NMDA receptor complex
111. Age-related changes in excitatory amino acid receptors in two mouse strains
112. Age-related changes in the expression of NMDA receptor subunits
113. Synaptic plasticity in the hippocampus: LTP and LTD
114. NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers
115. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: A study with ketamine
116. General anesthetics
117. Impaired hippocampal representation of space in CA1-specific NMDAR1 knockout mice
118. MK-801 impedes the acquisition of a spatial memory task in rats
119. The neuropharmacological and neurochemical basis of place learning in the Morris water maze
120. Glutamate receptor expression in schizophrenic brain
121. Neural correlates of working memory in a visual letter monitoring task: An fMRI study
122. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex
123. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia
124. NMDA receptor antagonists can enhance or impair learning performance in animals
125. Heteromeric NMDA receptors: Molecular and functional distinction of subtypes
126. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors
127. Synaptic plasticity and learning: Selective impairment of learning rats and blockade of long-term potentiation in vivo by the N-methyl-D-aspartate receptor antagonist AP5
128. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5
129. Hippocampal synaptic plasticity and NMDA receptors: A role in information storage?
130. Effects of prolonged infusions of the NMDA antagonist aptiganel hydrochloride (CNS 1102) in normal volunteers
131. Molecular diversity of glutamate receptors and implications for brain function
132. Guanabenz effects on NMDA antagonist-induced mental symptoms in humans
133. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis
134. NMDA antagonist-induced decreases in working and explicit memory in humans
135. NMDA receptor function, memory and brain aging
136. Hippocampal synaptic plasticity in mice overexpressing an embryonic subunit of the NMDA receptor
137. Excitatory transmitters and neuropsychiatric disorders
138. Excitotoxic amino acids and neuropsychiatric disorders
139. Glutamate receptor dysfunction and schizophrenia
140. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs
141. NMDA antagonist neurotoxicity: Mechanism and prevention
142. Excitotoxic neurodegeneration in Alzheimer disease; new hypothesis and new therapeutic strategies
143. Clinical studies of induction agents. XXXVII. Amnesic action of ketamine
144. Excitatory amino acid antagonists and memory: Effect of drugs acting at N-methyl-D-aspartate receptors in learning and memory tasks
145. Dissociative anesthesia
146. [3H]MK-801 binding to the NMDA receptor complex, and its modulation in human frontal cortex during development and aging
147. N-methyl-D-aspartate antagonists and working memory performance: Comparison with the effects of scopolamine, propranolol, diazepam, and phenylisopropyladenosine
148. Glycine in the treatment of schizophrenia: Theory and preliminary results
149. Enrichment induces structural changes and recovery from nonspatial memory deficits in CA1 NMDAR1-knockout mice
150. Ketamine: An update on the first twenty-five years of clinical experience
151. Long-term potentiation and N-methyl-D-aspartate receptors: Foundations of memory and neurologic disease
152. Comparison of sernyl with other drugs: Simulation of schizophrenic performance with sernyl, LSD-25, and amobarbital (amytal): I. Attention, motor function, and proprioception
153. Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: An open label pilot study
154. D-cycloserine adjuvant therapy to molidone in the treatment of schizophrenia
155. Selective loss of glial glutamate transporter GLT-1 in amyotropic lateral sclerosis
156. Reduced hippocampal LTP and spatial learning in mice lacking NMDA receptor epsilon 1 subunit
157. Dizocilpine binding to cerebral cortical membranes from developing and ageing mice
158. Neuropsychological function in schizophrenia. Selective impairment in memory and learning
159. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia
160. Haloperidol prevents induction of the hsp70 heat shock gene in neurons injured by phencyclidine (PCP), MK801, and ketamine
161. Phencyclidine induction of the hsp70 stress gene in injured pyramidal neurons is mediated via multiple receptors and voltage gated calcium channels
162. DNQX inhibits phencyclidine (PCP) and ketamine induction of the hsp70 heat shock gene in the rat cingulate and retrosplenial cortex
163. Changing subunit composition of heteromeric NMDA receptors during development of rat cortex
164. Evidence of glutamatergic deficiency in schizophrenia
165. NMDA receptor-dependent synaptic reinforcement as a crucial process for memory consolidation
166. Dissociating verbal and spatial working memory using PET
167. Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of "neuroleptic-free" schizophrenics: Evidence on reversible up-regulation by typical neuroleptics
168. NMDA receptor channel antagonism by dizocilpine (MK-801) impairs performance of rats in aversively motivated complex maze tasks
169. Prefrontal activation during a nonspatial working memory task
170. Synaptic disinhibition during maintenance of long-term potentiation in the CA 1 hippocampal subfield
171. Genetic enhancement of learning and memory in mice
172. Phencyclidine in combination with d-amphetamine: Differential effects on acquisition and performance of response chains in monkeys
173. Effects of phencyclidine, ketamine and MDMA on complex operant behavior in monkeys
174. Intra-ventricular infusion of the NMDA antagonist AP5 impairs performance on a non-spatial operant DRL task in the rat
175. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains
176. D-Serine added to antipsychotics for the treatment of schizophrenia
177. The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory
178. Decreased expression of N-methyl-D-aspartate receptor 1 messenger RNA in select regions of Alzheimer brain
179. Efficacy and tolerance of D-cycloserine in drug free schizophrenic patients
180. Interaction of phencyclidine ('angel dust") with a specific receptor in rat brain membranes
181. Effects of the novel NMDA antagonist, NPC 12626, on long-term potentiation, learning and memory
182. Effects of the NMDA antagonists CPP and MK-801 on radial arm maze performance in rats
183. Glycine therapy of schizophrenia
184. PCP intoxication in young children and infants
185. Loss of NMDA, but not GABA-A, binding in the brains of aged rats and monkeys
186. Disseminated corticolimbic neuronal degeneration induced in rat brain by MK-801: Potential relevance to Alzheimer's disease
187. Acute phencyclidine (PCP) intoxication: Psychopathology and prognosis
188. Specific [3H]phencyclidine binding in rat central nervous system